DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors

Abstract Role of DNA damage and demethylation on anticancer activity of DNA methyltransferase inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene deletion/disruption (DNMT1 −/− ) on anticancer activity of a class of DNMTi in vitro, in vivo and in human cancers. The gene deletio...

Full description

Bibliographic Details
Main Authors: Angelo B. A. Laranjeira, Melinda G. Hollingshead, Dat Nguyen, Robert J. Kinders, James H. Doroshow, Sherry X. Yang
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-32509-4
_version_ 1827966372889493504
author Angelo B. A. Laranjeira
Melinda G. Hollingshead
Dat Nguyen
Robert J. Kinders
James H. Doroshow
Sherry X. Yang
author_facet Angelo B. A. Laranjeira
Melinda G. Hollingshead
Dat Nguyen
Robert J. Kinders
James H. Doroshow
Sherry X. Yang
author_sort Angelo B. A. Laranjeira
collection DOAJ
description Abstract Role of DNA damage and demethylation on anticancer activity of DNA methyltransferase inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene deletion/disruption (DNMT1 −/− ) on anticancer activity of a class of DNMTi in vitro, in vivo and in human cancers. The gene deletion markedly attenuated cytotoxicity and growth inhibition mediated by decitabine, azacitidine and 5-aza-4′-thio-2′-deoxycytidine (aza-T-dCyd) in colon and breast cancer cells. The drugs induced DNA damage that concurred with DNMT1 inhibition, subsequent G2/M cell-cycle arrest and apoptosis, and upregulated p21 in DNMT1 +/+ versus DNMT1 −/− status, with aza-T-dCyd the most potent. Tumor growth and DNMT1 were significantly inhibited, and p21 was upmodulated in mice bearing HCT116 DNMT1+/+ xenograft and bladder PDX tumors. DNMT1 gene deletion occurred in ~ 9% human colon cancers and other cancer types at varying degrees. Decitabine and azacitidine demethylated CDKN2A/CDKN2B genes in DNMT1 +/+ and DNMT1 −/− conditions and increased histone-H3 acetylation with re-expression of p16INK4A/p15INK4B in DNMT1 −/− state. Thus, DNMT1 deletion confers resistance to DNMTi, and their anti-cancer activity is determined by DNA damage effects. Patients with DNMT1 gene deletions may not respond to DNMTi treatment.
first_indexed 2024-04-09T17:47:55Z
format Article
id doaj.art-22f1c29b81fd48fabfcfb740b7c77fa9
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-09T17:47:55Z
publishDate 2023-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-22f1c29b81fd48fabfcfb740b7c77fa92023-04-16T11:11:34ZengNature PortfolioScientific Reports2045-23222023-04-0113111210.1038/s41598-023-32509-4DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitorsAngelo B. A. Laranjeira0Melinda G. Hollingshead1Dat Nguyen2Robert J. Kinders3James H. Doroshow4Sherry X. Yang5Division of Cancer Treatment and Diagnosis, National Cancer InstituteDivision of Cancer Treatment and Diagnosis, National Cancer InstituteDivision of Cancer Treatment and Diagnosis, National Cancer InstituteLeidos Biomedical Research, Inc.Division of Cancer Treatment and Diagnosis, National Cancer InstituteDivision of Cancer Treatment and Diagnosis, National Cancer InstituteAbstract Role of DNA damage and demethylation on anticancer activity of DNA methyltransferase inhibitors (DNMTi) remains undefined. We report the effects of DNMT1 gene deletion/disruption (DNMT1 −/− ) on anticancer activity of a class of DNMTi in vitro, in vivo and in human cancers. The gene deletion markedly attenuated cytotoxicity and growth inhibition mediated by decitabine, azacitidine and 5-aza-4′-thio-2′-deoxycytidine (aza-T-dCyd) in colon and breast cancer cells. The drugs induced DNA damage that concurred with DNMT1 inhibition, subsequent G2/M cell-cycle arrest and apoptosis, and upregulated p21 in DNMT1 +/+ versus DNMT1 −/− status, with aza-T-dCyd the most potent. Tumor growth and DNMT1 were significantly inhibited, and p21 was upmodulated in mice bearing HCT116 DNMT1+/+ xenograft and bladder PDX tumors. DNMT1 gene deletion occurred in ~ 9% human colon cancers and other cancer types at varying degrees. Decitabine and azacitidine demethylated CDKN2A/CDKN2B genes in DNMT1 +/+ and DNMT1 −/− conditions and increased histone-H3 acetylation with re-expression of p16INK4A/p15INK4B in DNMT1 −/− state. Thus, DNMT1 deletion confers resistance to DNMTi, and their anti-cancer activity is determined by DNA damage effects. Patients with DNMT1 gene deletions may not respond to DNMTi treatment.https://doi.org/10.1038/s41598-023-32509-4
spellingShingle Angelo B. A. Laranjeira
Melinda G. Hollingshead
Dat Nguyen
Robert J. Kinders
James H. Doroshow
Sherry X. Yang
DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
Scientific Reports
title DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
title_full DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
title_fullStr DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
title_full_unstemmed DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
title_short DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
title_sort dna damage demethylation and anticancer activity of dna methyltransferase dnmt inhibitors
url https://doi.org/10.1038/s41598-023-32509-4
work_keys_str_mv AT angelobalaranjeira dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors
AT melindaghollingshead dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors
AT datnguyen dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors
AT robertjkinders dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors
AT jameshdoroshow dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors
AT sherryxyang dnadamagedemethylationandanticanceractivityofdnamethyltransferasednmtinhibitors